Sygnature and Cyprotex will collaborate to provide an integrated discovery chemistry/DMPK service to accelerate their clients' drug-discovery projects into development.
Sygnature Chemical Services provides medicinal and computational chemistry services to the global pharmaceutical industry, while Cyprotex Discovery is a pre-clinical discovery and development CRO with a core focus on ADME/PK.
